Bio-Rad's reputation in addition to its existence in both clinical and research marketplaces will be necessary elements to the success of the GnuBIO system. We have become excited to become listed on the Bio-Rad family members, Boyce added.. Bio-Rad Laboratories buys GnuBIO GnuBIO, a privately-held lifestyle sciences company which has developed a droplet-based DNA sequencing technology, today announced that it had been acquired by Bio-Rad Laboratories, Inc. With this acquisition, Bio-Rad will broaden its Digital Biology Middle and set up a research and advancement site in Cambridge, Massachusetts.The researchers also right now hope to adapt it for make use of in central venous catheters which are used to deliver cancer medicines and nourishment, and urinary catheters, which are commonly used in the healthcare of older people and to manage urinary system problems in people with spinal accidental injuries and spina bifida. This will involve some adaptation to cover particular pathogens such as, in the entire case of foley catheters, Proteus which creates a biofilm on the converts and catheter urea in urine into ammonia, causing phosphates and minerals to form an agonizing crystallised crust in the neck of the catheter. This in convert can lead to bladder infections and, if still left untreated, the more serious condition of pyelonephritis which destroys the kidneys by turning them into scar tissue formation and causes renal failure.